TherapeuticsMD Q2 net income falls to $164 thousand as license revenue declines
TherapeuticsMD reported second quarter 2026 results, with net income from continuing operations of $164 thousand, down from $545 thousand a year earlier, and license revenue of $869 thousand, down from $952 thousand. The company continues to explore strategic alternatives, including a possible acquisition, merger, or sale of assets, but says there is no assurance of a transaction and has set no timetable.
Key points
- Net income from continuing operations: $164 thousand in Q2 2026 vs. $545 thousand in Q2 2025.
- License revenue: $869 thousand in Q2 2026 vs. $952 thousand in Q2 2025, attributed to changes in sales of licensed products.
- Total operating expenses rose $38 thousand, or 2.3%, to $1.7 million, mainly due to higher general and administrative expenses and patent write-offs.
- Cash and cash equivalents were $9.2 million as of June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.